Four-Drug attack on advanced skin cancer aims to boost effectiveness, reduce side effects
NCT ID NCT05428007
Summary
This study is testing whether adding a drug called sarilumab to a combination of three other immunotherapy drugs works better for people with advanced melanoma that cannot be removed by surgery. The main goals are to see if this four-drug combination is safe, tolerable, and more effective at shrinking or controlling tumors than the three-drug combination alone. About 105 adults with stage III or IV melanoma will participate to help researchers find out.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-••••
Contact
-
The Angeles Clinic at Cedars Sinai
RECRUITINGLos Angeles, California, 90025, United States
Contact
Conditions
Explore the condition pages connected to this study.